Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.…
Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial
Novavax (NASDAQ: NVAX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 749 employees.
The shares were at 7.470 USD on 20 November 2026, roughly unchanged over 52 weeks. Its 52-week range is 6.200 USD to 13.38 USD: the price is 44.2% below the high and 20.5% above the low.
Its market capitalisation is 1.23B USD.
Novavax reports return on equity of -344.7%, an operating margin of -17.0% and revenue down 3.0% year over year.
It holds more cash than debt, a net cash position of 327.10M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 14.11 USD is 88.9% above the current price. The next earnings report is expected on 25 February 2027.